Payment overview · 2025
General Payments
$865.77
7 reported records · 5 companies
Healthcare provider profile · identity verified
Shanthi A Joseph, MD
Allopathic & Osteopathic Physicians|Internal Medicine · APPLETON, WI · NPI 1417941212
Verified facts
What the public records show
CMS Open Payments records show Shanthi A Joseph, MD received $865.77 in general payments during 2025 across 7 reported records.
Saluda Medical Americas, Inc. accounted for 45.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $392.79 | 45.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $227.57 | 26.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.50 | 14.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $104.07 | 12.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.84 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $865.77 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $392.79 | 2 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $227.57 | 2 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $227.57 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $124.50 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $104.07 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 550 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 542 | 125 |
| Atorvastatin Calcium | Atorvastatin Calcium | 460 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 412 | 111 |
| Lisinopril | Lisinopril | 411 | 99 |
| Omeprazole | Omeprazole | 394 | 115 |
| Losartan Potassium | Losartan Potassium | 365 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 287 | 74 |
| Gabapentin | Gabapentin | 276 | 61 |
| Simvastatin | Simvastatin | 248 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 232 | 85 |
| Furosemide | Furosemide | 231 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 219 | 57 |
| Metformin Hcl Er | Metformin Hcl | 200 | 58 |
| Famotidine | Famotidine | 179 | 43 |
| Eliquis | Apixaban | 177 | 37 |
| Potassium Chloride | Potassium Chloride | 171 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 170 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 169 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 164 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 164 | 39 |
| Alendronate Sodium | Alendronate Sodium | 159 | 50 |
| Sertraline Hcl | Sertraline Hcl | 149 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 148 | 24 |
| Lovastatin | Lovastatin | 147 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 142 | 32 |
| Trazodone Hcl | Trazodone Hcl | 133 | 42 |
| Mirtazapine | Mirtazapine | 119 | 32 |
| Atenolol | Atenolol | 115 | 27 |
| Bupropion Xl | Bupropion Hcl | 112 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 19 |
| Metformin Hcl | Metformin Hcl | 99 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 85 | 21 |
| Jardiance | Empagliflozin | 85 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 85 | 22 |
| Valsartan | Valsartan | 83 | 18 |
| Synthroid | Levothyroxine Sodium | 79 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 79 | 16 |
| Glimepiride | Glimepiride | 76 | 22 |
| Tramadol Hcl | Tramadol Hcl | 75 | 19 |
| Glipizide Er | Glipizide | 68 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 15 |
| Montelukast Sodium | Montelukast Sodium | 63 | 15 |
| Pregabalin | Pregabalin | 61 | 14 |
| Spironolactone | Spironolactone | 61 | 21 |
| Prednisone | Prednisone | 60 | 45 |
| Warfarin Sodium | Warfarin Sodium | 59 | 12 |
| Allopurinol | Allopurinol | 58 | 13 |
| Ozempic | Semaglutide | 58 | 12 |
| Lorazepam | Lorazepam | 56 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 20 |
| Sodium Chloride | 0.9 % Sodium Chloride | 52 | suppressed |
| Estradiol | Estradiol | 48 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 47 | 13 |
| Carvedilol | Carvedilol | 44 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | suppressed |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 11 |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 29 |
| Ezetimibe | Ezetimibe | 37 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 14 |
| Arnuity Ellipta | Fluticasone Furoate | 36 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 29 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 34 | 11 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | 11 |
| Azithromycin | Azithromycin | 29 | 27 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Probenecid | Probenecid | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 12 |
| Acyclovir | Acyclovir | 23 | 12 |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 16 |
| Nystatin | Nystatin | 23 | 13 |
| Cephalexin | Cephalexin | 22 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Nystop | Nystatin | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $865.77 · 7 records | Saluda Medical Americas, Inc. | Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Evoke, General - Pain Management, JARDIANCE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error